David A. Siegel Cyclerion Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.43 - $0.9 $2,494 - $5,220	-5,800 Reduced 24.37%	18,000 $7,000
Q4 2022 Feb 14, 2023	SELL	$0.42 - $18.8 $5,376 - $240,640	-12,800 Reduced 34.97%	23,800 $15,000
Q3 2022 Nov 14, 2022	SELL	$0.58 - $18.2 $34,858 - $1.09 Million	-60,100 Reduced 62.15%	36,600 $31,000
Q2 2022 Aug 15, 2022	SELL	$0.47 - $1.29 $55,648 - $152,736	-118,400 Reduced 55.04%	96,700 $53,000
Q1 2022 May 16, 2022	SELL	$0.96 - $1.78 $294,048 - $545,214	-306,300 Reduced 58.75%	215,100 $239,000
Q4 2021 Feb 14, 2022	SELL	$1.56 - $2.99 $197,028 - $377,637	-126,300 Reduced 19.5%	521,400 $897,000
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.13 $876,876 - $1.33 Million	321,200 Added 98.38%	647,700 $1.99 Million
Q2 2021 Aug 16, 2021	BUY	$2.18 - $4.29 $341,606 - $672,243	156,700 Added 92.29%	326,500 $1.27 Million
Q1 2021 May 17, 2021	BUY	$2.69 - $5.12 $304,508 - $579,584	113,200 Added 200.0%	169,800 $474,000
Q4 2020 Feb 16, 2021	BUY	$2.25 - $7.12 $127,350 - $402,992	56,600 New	56,600 $173,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $114M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.